Literature DB >> 17396261

Highly aggressive ALK-positive anaplastic large cell lymphoma with a leukemic phase and multi-organ involvement: a report of three cases and a review of the literature.

Jaspreet S Grewal1, Lauren B Smith, Jerome D Winegarden, John C Krauss, Joseph A Tworek, Bertram Schnitzer.   

Abstract

Anaplastic large cell lymphoma (ALCL) is an aggressive neoplasm of T- or null cell phenotype and is recognized as a distinct clinicopathologic subtype of non-Hodgkin lymphoma (NHL) in the revised World Health Organization (WHO) classification of hematopoietic neoplasms. It is rarely associated with leukemic phase. Most cases with leukemic involvement are the small cell variant of ALCL. These cases often lack the pleomorphism seen in the common variant of ALCL and may be misdiagnosed. We report a series of three patients who presented with leukemic phase ALCL. The patients included an 11-year-old boy, a 29-year-old man, and a 59-year-old woman. The clinical and pathologic features of these cases are reviewed. The patients in our case series with leukemic phase ALCL exhibited rare clinical features. The patients presented with massive extranodal disease involving cerebrospinal fluid (CSF), liver, spleen, lungs, and bone marrow. CSF involvement was documented morphologically as well as by flow cytometry in two patients. Two of the patients had small cell variant and the third patient had common type ALCL. The neoplastic cells in all three patients were ALK positive; however these patients died within months of diagnosis. Leukemic phase ALCL is rare, and behaves in an aggressive manner. Some, but not all, cases in the literature presenting with peripheral blood involvement had small cell variant ALCL, as seen in two of our cases. The leukemic phase of ALCL should be considered when a T-cell leukemia with unusual morphologic features is encountered.

Entities:  

Mesh:

Substances:

Year:  2007        PMID: 17396261     DOI: 10.1007/s00277-007-0289-3

Source DB:  PubMed          Journal:  Ann Hematol        ISSN: 0939-5555            Impact factor:   3.673


  10 in total

1.  Convergent mutations and kinase fusions lead to oncogenic STAT3 activation in anaplastic large cell lymphoma.

Authors:  Ramona Crescenzo; Francesco Abate; Elena Lasorsa; Fabrizio Tabbo'; Marcello Gaudiano; Nicoletta Chiesa; Filomena Di Giacomo; Elisa Spaccarotella; Luigi Barbarossa; Elisabetta Ercole; Maria Todaro; Michela Boi; Andrea Acquaviva; Elisa Ficarra; Domenico Novero; Andrea Rinaldi; Thomas Tousseyn; Andreas Rosenwald; Lukas Kenner; Lorenzo Cerroni; Alexander Tzankov; Maurilio Ponzoni; Marco Paulli; Dennis Weisenburger; Wing C Chan; Javeed Iqbal; Miguel A Piris; Alberto Zamo'; Carmela Ciardullo; Davide Rossi; Gianluca Gaidano; Stefano Pileri; Enrico Tiacci; Brunangelo Falini; Leonard D Shultz; Laurence Mevellec; Jorge E Vialard; Roberto Piva; Francesco Bertoni; Raul Rabadan; Giorgio Inghirami
Journal:  Cancer Cell       Date:  2015-04-13       Impact factor: 31.743

2.  Leukemic presentation of ALK-positive anaplastic large cell lymphoma with a novel partner, poly(A) binding protein cytoplasmic 1 (PABPC1), responding to single-agent crizotinib.

Authors:  Dylan Graetz; Kristine R Crews; Elizabeth M Azzato; Ravi K Singh; Susana Raimondi; John Mason; Marcus Valentine; Charles G Mullighan; Ashley Holland; Hiroto Inaba; Vasiliki Leventaki
Journal:  Haematologica       Date:  2019-02-28       Impact factor: 9.941

3.  A novel patient-derived tumorgraft model with TRAF1-ALK anaplastic large-cell lymphoma translocation.

Authors:  F Abate; M Todaro; J-A van der Krogt; M Boi; I Landra; R Machiorlatti; F Tabbò; K Messana; C Abele; A Barreca; D Novero; M Gaudiano; S Aliberti; F Di Giacomo; T Tousseyn; E Lasorsa; R Crescenzo; L Bessone; E Ficarra; A Acquaviva; A Rinaldi; M Ponzoni; D L Longo; S Aime; M Cheng; B Ruggeri; P P Piccaluga; S Pileri; E Tiacci; B Falini; B Pera-Gresely; L Cerchietti; J Iqbal; W C Chan; L D Shultz; I Kwee; R Piva; I Wlodarska; R Rabadan; F Bertoni; G Inghirami
Journal:  Leukemia       Date:  2014-12-23       Impact factor: 11.528

4.  Aggressive transformation of anaplastic large cell lymphoma with increased number of ALK-translocated chromosomes.

Authors:  Akihiro Hoshino; Keiko Nomura; Takeru Hamashima; Tomoya Isobe; Masafumi Seki; Mitsuteru Hiwatari; Kenichi Yoshida; Yuichi Shiraishi; Kenichi Chiba; Hiroko Tanaka; Satoru Miyano; Seishi Ogawa; Junko Takita; Hirokazu Kanegane
Journal:  Int J Hematol       Date:  2014-11-22       Impact factor: 2.490

Review 5.  Beyond NPM-anaplastic lymphoma kinase driven lymphomagenesis: alternative drivers in anaplastic large cell lymphoma.

Authors:  Fabrizio Tabbò; Maurilio Ponzoni; Raul Rabadan; Francesco Bertoni; Giorgio Inghirami
Journal:  Curr Opin Hematol       Date:  2013-07       Impact factor: 3.284

Review 6.  Successful treatment of small cell variant anaplastic large cell lymphoma with allogeneic peripheral blood stem cell transplantation, and review of the literature.

Authors:  Rie Imamura; Fumihiko Mouri; Kei Nomura; Takayuki Nakamura; Eijiro Oku; Satoshi Morishige; Yuka Takata; Ritsuko Seki; Koichi Osaki; Michitoshi Hashiguchi; Koji Yoshimoto; Koichi Ohshima; Koji Nagafuji; Takashi Okamura
Journal:  Int J Hematol       Date:  2012-12-20       Impact factor: 2.490

7.  Small cell variant of anaplastic large cell lymphoma with leukemic presentation: a diagnostic challenge.

Authors:  Tomás Zecchini Barrese; Carlo Sagramoso; Francesco Bacci; Elena Sabattini
Journal:  Rev Bras Hematol Hemoter       Date:  2017-06-27

8.  Decreased MYC-associated factor X (MAX) expression is a new potential biomarker for adverse prognosis in anaplastic large cell lymphoma.

Authors:  Takahisa Yamashita; Morihiro Higashi; Shuji Momose; Akiko Adachi; Toshiki Watanabe; Yuka Tanaka; Michihide Tokuhira; Masahiro Kizaki; Jun-Ichi Tamaru
Journal:  Sci Rep       Date:  2020-06-25       Impact factor: 4.379

9.  Rapidly progressing primary pulmonary lymphoma masquerading as lung infectious disease: A case report and review of the literature.

Authors:  Jin-Hong Jiang; Chun-Lai Zhang; Qin-Li Wu; Yong-Hua Liu; Xiao-Qiu Wang; Xiao-Li Wang; Bing-Mu Fang
Journal:  World J Clin Cases       Date:  2021-06-06       Impact factor: 1.337

10.  The Leukemic Phase of ALK-Negative Anaplastic Large Cell Lymphoma Is Associated with CD7 Positivity, Complex Karyotype, TP53 Deletion, and a Poor Prognosis.

Authors:  Lianqun Qiu; L Jeffrey Medeiros; Guilin Tang; Mahsa Khanlari; Shaoying Li; Sergej Konoplev; Sa A Wang; C Cameron Yin; Joseph D Khoury; Wei Wang; Roberto N Miranda; Swaminathan Iyer; M James You; Jie Xu
Journal:  Cancers (Basel)       Date:  2021-12-16       Impact factor: 6.639

  10 in total

北京卡尤迪生物科技股份有限公司 © 2022-2023.